Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Enrollment complete in U.S. trial of selective amyloid lowering drug for Alzheimer disease
September 20th, 2006
Myriad Genetics, Inc. (MYGN) announced that it has completed enrollment in its U.S. phase 3 clinical trial of Flurizan for patients with Alzheimer disease. Flurizan is the first in a new class of investigative drugs known as selective amyloid lowering agents (SALAs). This mechanism is different from the currently marketed drugs for Alzheimer disease that provide a limited, temporary cognitive boost without affecting the course of the disease itself. Flurizan is not an NSAID and does not inhibit COX1 or COX2 enzymes. With a safety database consisting of over 600 patient-years of exposure data, Myriad has not seen gastrointestinal toxicity attributable to Flurizan. ...
Source: Biotech Week (2006-09-20)
|
